Stocktoria
Allogene Therapeutics, Inc. ALLO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-11
Allogene Therapeutics, Inc. statistics & valuation
Market cap$735.2M
P / B2.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -1241813.6% | -344986.3% | -215087.2% | -157.9% |
| Net margin | — | -1170863.6% | -344489.5% | -218214.1% | -159.6% |
| FCF margin | — | -913609.1% | -251841.1% | -144685.9% | -180.8% |
| Return on assets | -45.9% | -46.9% | -50.9% | -41.4% | -17.5% |
| Return on equity | -65.3% | -61.0% | -63.9% | -51.0% | -19.7% |
| Current ratio | 7.93 | 8.54 | 12.38 | 9.84 | 9.78 |
| Revenue growth | -100.0% | -76.8% | -39.1% | -99.9% | — |
Source: SEC EDGAR filings · CIK 0001737287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.